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Background: Asthma affects up to 33% of children in Latin American settings. The ongoing
COVID-19 pandemic has had a significant impact on access to and use of health services. We
aimed to evaluate the impact of the COVID-19 lockdown on asthma exacerbations, medical facility
visits, and use of asthma medications in children.
Methods: We used data from a prospective cohort of 213 children aged 5–17 years in 3 Ecua-
dorian cities and analysed the impact of the COVID-19 lockdown on asthma. Outcomes (asthma
exacerbations, emergency room [ER] visits, planned and unplanned outpatient visits, and use of
inhaled corticosteroids and Beta-2 agonists) were analysed using repeated Poisson counts (ie,
number of events per participant before and during the COVID-19 lockdown).
Results: During compared to before lockdown: a) the number of asthma exacerbations remained
constant (IRR, 0.87; 95% CI: 0.72–1.05; p ¼ 0.152); b) outpatient visits (IRR 0.26, 95% CI 0.14–0.47,
p < 0.001) declined 74% while ER visits declined 89% (IRR 0.11, 95% CI 0.04–0.32, p < 0.001); and
c) there was no change in inhaled corticosteroids use (IRR 1.03, 95% CI 0.90–1.16, P ¼ 0.699) while
Beta-2 agonist use increased (IRR 1.32, 95% CI 1.10–1.58, P ¼ 0.003).
Conclusions: In a cohort of Ecuadorian children with asthma, health services attendance
decreased dramatically after COVID-19 lockdown, but asthma exacerbations and use of inhaled
corticosteroids were unchanged. Future analyses will address the question of the effect of SARS-
CoV-2 infection on asthma exacerbations and control in this paediatric population.
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Asthma is the most common children’s chronic
disease and is estimated to affect between 9% and
33% of children in Latin American settings.1–4 The
ongoing COVID-19 pandemic has had a signifi-
cant impact on access to and use of health ser-
vices.5,6 Data from US hospital records and online
surveys of health-care providers have docu-
mented major reductions in emergency room (ER)
visits,7 uptakes of follow-up visits, prescriptions,
treatment adherence,6,8 and asthma control.5,9
Similarly, hospital records analysis in Japan
revealed a decrease in asthma hospitalisations
during the pandemic.10 Such reductions likely
reflect the combined effects of stay-at-home or-
ders, reassignment of health services, fear of
contagion or reduction of severe asthma attacks.
There are limited data on the effects of COVID-19
on children with asthma. A recent multicentre
case-control analysis of asthmatic children
attending outpatient visits showed improved
asthma outcomes and control during the COVID-
19 pandemic.11 To our knowledge, there are no
prospective published studies of the effect of
COVID-19 control measures on asthma symptoms
and management. In the present analysis, we used
data from an ongoing prospective study of asthma
in children and adolescents in 3 large Ecuadorian
cities to study the impact of the implementation of
lockdown measures to control the COVID-19
pandemic in Ecuador on the risk of asthma exac-
erbations, planned and unplanned health facility
visits, and use of asthma medications.METHODS
Study design, and context
We used data from a prospective cohort study
of children aged 5–17 years old being done in 3
cities in Ecuador (Quito, Cuenca, and Portoviejo)
to identify risk factors for asthma exacerbations.
Quito and Cuenca are located in the Andean
highlands at 2500 m altitude, while Portoviejo is
located in the coastal plains below 100 m. In
Ecuador, mandatory COVID-19 lockdown pro-
visions were implemented for 6 months between
March 14 and September 13, 2020, and
included stay-at-home orders, school and uni-
versity closures, mandatory use of masks in
public places, social distancing, prioritisation ofteleworking, mobility restrictions, and curfews.
Many public hospitals were assigned exclusively
to COVID-19 emergency care, and planned
outpatient appointments were cancelled during
the lockdown.Recruitment
Children and adolescents attending emergency
rooms (ERs) in public hospitals with an acute
asthma attack between April 2019 and February
2020 were invited to participate. Baseline infor-
mation on sociodemographic data, asthma symp-
toms, and management of the previous 12 months
was collected within 3 weeks of initial ER atten-
dance. After the initial ER visit, outpatient follow-up
appointments (either with a paediatric pneumolo-
gist or a paediatrician, depending on availability)
were scheduled by hospital staff. Each specialist
prescribed maintenance treatment without any
intervention from the research team.
The research staff performed monthly follow-
ups for the next 12 months through face-to-face
meetings or by telephone interviews with parents
or guardians to register occurrence of asthma ex-
acerbations and symptoms, attendances at
healthcare facilities, and ongoing treatments. The
research staff did not prescribe medications but
did provide free medications when not available
within the public hospital pharmacies but only in
accordance with the hospital specialists’ pre-
scriptions. At the start of COVID-19 lockdown, all
scheduled face-to-face meetings were changed to
monthly telephone interviews.Clinical outcomes
The clinical outcomes of primary interest were
collected during the monthly follow-ups. The par-
ents/guardians were interviewed to collect data on
asthma exacerbations (including exact dates of
occurrence), health facilities visits, and use on
asthma medications in the previous month. Out-
comes included: 1) asthma exacerbations defined
as the number of parentally reported acute asthma
attacks or wheezing episodes with respiratory
distress; 2) number of ER visits; 3) number of
outpatient visits including scheduled or unsched-
uled medical appointments for asthma (not
including project-related activities for follow-up);
4) inhaled corticosteroid use defined by the
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usage in the previous month, and; 5) Beta-2
agonist usage defined by the number of follow-
ups with Beta-2 agonist use in the previous
month. All outcomes were evaluated before the
COVID-19 lockdown (December 12, 2019 to
March 31, 2020) and during the COVID-19 lock-
down (April 1 to July 12, 2020). Fig. 1 shows
examples of follow-up time included in the anal-
ysis for 3 study participants before and during
COVID-19 lockdown. To assure the correct alloca-
tion of the exacerbations in the “before lockdown”
or “during lockdown” periods, considering that
monthly follow-up data was collected for the pre-
vious month, all data collected until March 31,
2020 were classified as “before lockdown period”.
Next, all the dates of the reported exacerbations
were checked, if an exacerbation was misclassified
in the “before lockdown” or “during lockdown
period” it was reallocated. Data were entered us-
ing ODK (Opendata kit v1.21.1 ODK Inc.) on mo-
bile devices.
Statistical analyses
Outcomes were analysed as repeated Poisson
counts, assessed as the number of events per
participant before and during COVID-19 re-
strictions, with associated offsets representing
follow-up time potentially censored by the dates
corresponding to 3 months before and during the
lockdown. The associated offsets accommodate
different periods of follow-up for each period for
every child. Population averaged models were
fitted for each outcome assuming exchangeable
correlation structure and incidence rate ratios
(IRRs) comparing monthly rates of events beforeFig. 1 Example of follow-up time for three subjects used for estimation
19 lockdownand during lockdown (Table 1). Statistical
significance was inferred by P < 0.05. Three-
month average incidence rates of outcomes were
also derived (Table 1). The analysis was performed
with and without adjustment for age and sex, using
Stata 12 (College Station, TX, USA).
Ethical considerations
Study protocol and procedures were approved
by the Ethics Committee of the Hospital Docente
de Calderón (approval, CEISH-HGDC 2019- 001).
Parents provided informed written consent, and
children over 12 years provided informed minor
consent. We provided inhaled corticosteroids to
patients when prescribed by specialists and un-
available in hospital pharmacies including during
the COVID-19 lockdown. During the monthly
follow-ups, the research staff delivered basic non-
pharmacological recommendations and contact
information for hospital specialists where appro-
priate. In addition, a short educational video
relating to COVID-19 and use of asthma medica-
tions was sent to all parents via social media, and
parents were invited to a webinar on asthma care
during the pandemic delivered by a paediatric
pneumologist (MM), an immunologist (CR) and an
infectious diseases physician.RESULTS
We recruited 213 children in 3 Ecuadorian cities
(Quito [n ¼ 52], Cuenca [n ¼ 98], and Portoviejo
[n ¼ 63]) with a mean age of 9.1 years (SD 2.9) of
whom 48.4% were female, 94.4% self-identified as
mestizo ethnicity (European-American indige-
nous), and 29.7% belonged to households with aof incidence rate ratios of outcomes during versus after the COVID-
Outcomes
During lockdown Total children  months follow
up ¼ 574













IRR (95% CI) P value
1-month 3-month 1-month 3-month
Evaluations
(follow-ups)
603 1.05 (0.97–1.14) 3.16 (2.92–3.43) 639 0.90 (0.83–0.97) 2.69 (2.50–2.90) 1.18 (1.05–1.32) 0.007
Asthma
exacerbations
181 0.32 (0.27–0.36) 0.95 (0.82–1.09) 258 0.36 (0.32–0.41) 1.09 (0.96–1.23) 0.89 (0.66–1.16) 0.436
Emergency
room visits
4 0.007 (0.003–0.018) 0.02 (0.01–0.06) 43 0.06 (0.04–0.08) 0.18 (0.13–0.24) 0.11 (0.04–0.32) <0.001
Outpatient
visits
13 0.023 (0.013–0.039) 0.07 (0.04–0.12) 61 0.085 (0.067–
0.111)




221 0.39 (0.34–0.43) 1.14 (1.00–1.30) 260 0.37 (0.33–0.42) 1.12 (0.98–1.26) 1.02 (0.90–1.16) 0.705
Beta-2 agonist
use
36 0.28 (0.24–0.32) 0.83 (0.71–0.96) 58 0.21 (0.18–0.25) 0.63 (0.53–0.74) 1.32 (1.10–1.59) 0.002
Table 1. Incidence rates (IR) of outcomes during and after the COVID-19 lockdown and the respective incidence rate ratios (IRR) Incidence rates (IR) and incidence rate ratios (IRR) were
estimated using Poisson regression models with offset indicating each child follow-up. P < 0.05 in bold. Evaluations - number of completed follow-ups; Asthma exacerbations – defined as acute attacks or asthma
symptoms with respiratory distress; Emergency room visits - number of emergency room visits; Outpatient visits – number of scheduled or unscheduled visits; Inhaled corticosteroid (ICS) use - number of follow-




















Fig. 2 Incidence rate ratios (IRR) for outcomes comparing rates
during versus before the COVID-19 lockdown. “Follow-ups”: the
number of follow-ups completed; “Exacerbate”: acute asthma
attacks or asthma symptoms with respiratory distress; “Outpatient”
- all scheduled or unscheduled outpatient visits reported;
“Emergency”: number of emergency room visits reported; “Inhaled
Cort” - number of follow-ups with inhaled corticosteroids usage in
the previous month; “Beta 2 adren” - number of follow-ups with
Beta-2 agonist use in the previous month
Volume 14, No. 6, Month 2021 5monthly income below the Ecuadorian minimum
wage (US$400).
Baseline data
All subjects were recruited after attending an ER
with an acute asthma attack. In the previous year
before the asthma attack, 83.2% reported
wheezing episodes, 17.4% had 4 or more epi-
sodes, and 29% had attended an ER more than
twice. Although most participants had a doctor’s
diagnosis of asthma (69.7%), only 25.3% and
10.1% had used a Beta-2 agonist or inhaled corti-
costeroids, respectively, during the previous year
prior to the asthma attack. At recruitment, 35.2% of
the participants were using Beta-2 agonists, and
19.7% inhaled corticosteroids.
Impact of the implementation of lockdown
measures on asthma outcomes
IRRs for outcomes comparing rates during
versus before COVID-19 lockdown are shown in
Fig. 2 and Table 1. Adjusting for age and sex did
not change the magnitude of the IRR estimates.
There was no significant change in the number of
reported asthma exacerbations during the
lockdown measures compared to before (IRR,
0.87; 95% CI: 0.72–1.05; p ¼ 0.152). However,
outpatient visits (IRR 0.26, 95% CI 0.14–0.47,
p < 0.001) declined 74%, while ER visits declined
89% (IRR 0.11, 95% CI 0.04–0.32, p < 0.001)
during lockdown. Interestingly, there was nochange in inhaled corticosteroids (IRR 1.03, 95%
CI 0.90–1.16, P ¼ 0.699), while Beta-2 agonist use
increased by a third (IRR 1.32, 95% CI 1.10–1.58,
P ¼ 0.003). The overall number of monthly follow-
ups increased during the lockdown (IRR 1.17, 95%
CI 1.05–1.32, P ¼ 0.007).DISCUSSION
We have analysed a cohort of asthmatic children
and adolescents in 3 Ecuadorian cities to deter-
mine the impact of the COVID-19 lockdown mea-
sures on the risk of asthma exacerbations, planned
and unplanned health facility visits, and medication
use. In Ecuador, strict measures were enforced for
the duration of the lockdown follow-up period in all
3 cities. Our data showed marked declines in the
use of health facilities but no impact on the number
of asthma exacerbations during the implementa-
tion of lockdown measures to control the spread of
COVID-19. Notably, the use of inhaled corticoste-
roids did not appear to be affected while that of
Beta-2 agonists increased after the lockdown.
To our knowledge, there are no published data
of the impact of COVID-19 lockdowns on asthma.
Although we did not collect data on potential ex-
posures to SARS-CoV-2 infections in the cohort,
the lack of severe exacerbations requiring ER
attendance could be interpreted as suggesting no
link with SARS-CoV-2 infection. Available data
indicate that asthma is not associated with an
increased risk of COVID-19 disease in adults,12
except perhaps those with severe disease,13 but
there is even less information on the relationship
between COVID-19 and paediatric asthma.7
Control measures during lockdown likely would
have reduced exposures to respiratory viruses11
that have been associated with 80% of asthma
exacerbations in children, with rhinoviruses being
particularly important.14 Several studies have
shown rhinovirus infections to be linked to
asthma exacerbations in children and
adolescents in tropical regions of Latin
America,15,16 although other respiratory viruses
such as influenza and respiratory syncytial virus
(RSV) may also have a role.17 Hospital admissions
for asthma in Ecuador tend to vary by region and
month with peak admissions in July through
September in the coastal region (Portoviejo) and
March through June in the highlands (Quito and
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differences in climate and circulation of
respiratory viruses. To our knowledge, there are
no published data on seasonality of rhinoviruses
or regional differences in the seasonal circulation
of other relevant respiratory viruses within
Ecuador; at a country level, RSV appears to peak
in March and influenza in December–January but
with marked inter-year variation.19 Given the
seasonal variations in asthma hospitalizations, an
increase in asthma attacks during the lockdown
period (from March 15) might have been
expected in the two highland study centers but
could have been masked by a probable decline
in the circulation of respiratory viral infections,
the main cause of asthma exacerbations,14 as a
consequence of the greater social isolation
during the COVID-19 lockdown.
Our findings are consistent with a recent inter-
national case-control study showing declines in ER
visits among children with asthma during the
COVID-19 pandemic.11 A generalised fear of
COVID-19 might have led children with acute ex-
acerbations to be managed at home rather than in
ERs, explaining the dramatic fall (89%) in ER at-
tendances and outpatient visits during lockdown.
We did not observe changes in risk of asthma ex-
acerbations during lockdown. In contrast, a recent
case-control study examining the effects of the
pandemic on several indicators of disease control
in children with asthma attending outpatient facil-
ities in 15 countries, showed a decline in asthma
attacks and hospitalisations during the pandemic,
although no account was taken of potential effects
of timing and strictness of lockdown measures on
these indicators.11 We did not assess the severity
of symptoms in our study, and it is quite possible
that there was a decline in severity rather than
the frequency of symptoms. Inhaled
corticosteroid use in our study population was
maintained unchanged during the lockdown,
which would have maximised asthma control. It
has been suggested that inhaled corticosteroids
may enhance innate immunity to viral
infections,14,15 reduce susceptibility to severe
respiratory viral infections,15 and in the case of
SARS-CoV-2, downregulate virus angiotensin-
converting enzyme-2 receptor (ACE2) expression
in the airways.16 The increase in Beta-2 agonist use
would indicate that patients did experiencesymptoms during lockdown – a previous study re-
ported an increase in the use of Beta-2 agonists
with worsening symptoms and delays in doctor
visits.20
In conclusion, our data from a prospective study
of paediatric asthma in Ecuador that compared
asthma exacerbations, use of health services, and
medication use before and during COVID-19
lockdown, showed dramatic reductions in the use
of health services but no impact on the number of
asthma exacerbations and use of inhaled cortico-
steroids. Future analyses of the cohort will address
the question of the effect of SARS-CoV-2 infection
on asthma exacerbations and control in this pae-
diatric population.Abbreviations
ACE2, angiotensin-converting enzyme-2; ER, emergency
room; IRR, incidence rate ratios; RSV, respiratory syncytial
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